Corticosteroid effectiveness in treating severe community acquired pneumonia

Phase 3

• Conditions: Health Condition 1: J189- Pneumonia, unspecified organism

• Registration Number: CTRI/2022/12/048583
• Lead Sponsor: GOVERNMENT MEDICAL COLLEGE AND HOSPITA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Age more than 18year.

2. Patients have clinical symptoms suggesting community acquired pneumonia (cough,

fever, pleuritic chest pain and/or shortness of breath)

3. Patient who will be diagnosed as a case of severe community acquired pneumonia as per the

criteria ATS IDSA 2007

4. Those who will give consent for study.

Exclusion Criteria

1. Immunocompromised patients i.e. HIV infection, neutropenic patients(1000Ã?109

/L), stem

cell transplant recipients, patients on immunosuppressive treatment other than

corticosteroid, patients of leukemia/lymphoma, chronic liver disease, chronic kidney

disease, coronary artery disease and/ or chronic heart failure.

2. Clinical suspicion of Tuberculosis

3. Gastrointestinal bleeding in past three months

4. Conditions requiring adjunctive long-term corticosteroid therapy (with an equivalent dose

of Inj methylprednisolone 1mg/kg/d or more)

5. Patients with pneumonia secondary to aspiration, hospital-acquired infection, prior

treatment in ICU or receipt of mechanical ventilation.

6. Evidence of empyema, cavitary lung lesion or lung abscess as a complication.

Study & Design

• Study Type: Interventional
• Study Design: Not specified